The Vietnam next generation sequencing market is projected to reach $222.53 million by 2036, at a CAGR of 12.6% from 2026 to 2036, up from an estimated $67.92 million in 2026. The market was valued at $60.40 million in 2025. The growth of this market is primarily fueled by rapid growth in cancer incidence, the establishment of a population-specific reference genome, and the expansion of privately funded genomic services. Additionally, migration toward domestic data processing under Vietnam's new Law on Personal Data Protection, procurement classification reform taking effect from 2027, and extension of sequencing into agricultural and veterinary applications are expected to create substantial growth opportunities for market participants.
According to IARC GLOBOCAN 2022 estimates, Vietnam recorded 180,480 new cancer cases and 120,184 cancer deaths, with new cases nearly doubling within a decade and forecast to rise a further 45% by 2045. The VN1K project, conducted at the VinGroup Big Data Institute with approximately $4.5 million committed, analysed 1,011 individuals from 53 of Vietnam's 63 provinces and identified more than 42 million genetic variants, of which approximately 8.5 million had never been recorded in major international databases, producing the Vietnamese PanGenome Reference published in Nature Communications in July 2026. By October 2022, 66 gene sequencers had been installed across Vietnamese healthcare facilities, and the largest gene sequencing centre in Southeast Asia opened in Hanoi.
The key players operating in the Vietnam next generation sequencing market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), F. Hoffmann La Roche Ltd. (Switzerland), Revvity, Inc. (U.S.), Pacific Biosciences of California, Inc. (U.S.), Danaher Corporation (U.S.), Oxford Nanopore Technologies plc (U.K.), MGI Tech Co., Ltd. (China), BGI Genomics Co., Ltd. (China), Eurofins Scientific SE (Luxembourg), and Novogene Co., Ltd. (China). In 2025, Illumina held the leading position in this market at an estimated 20% to 24% share, followed by Thermo Fisher Scientific at 11% to 15%, MGI Tech at 8% to 11%, QIAGEN at 6% to 8%, and BGI Genomics at 5% to 7%.
The Vietnam next generation sequencing market study presents historical market data value (2024, 2025), estimated current data (2026), and forecasts for 2036. This market is segmented by offering, application, and end user.
Among all the offerings, Commercial Sequencing and Outsourced Services account for the largest share of the market in 2026, driven by the outsourcing of not only sequencing capabilities but also data interpretation, a capability that Vietnamese institutions often lack. Data Analysis and Bioinformatics is expected to register the highest CAGR, as software and outsourced analysis substitute for interpretive staff that institutions cannot readily recruit.
Among all the applications, Clinical Applications represent the largest share of the market in 2026. Within this segment, Non-Invasive Prenatal Testing (NIPT) accounts for the largest share, driven by direct out-of-pocket payment by parents and relatively limited interpretive requirements. Oncology, meanwhile, is expected to experience the highest growth rate as tumor mutation testing expands from a comparatively smaller existing base.
Among all the end users, Hospitals, Clinical and Reference Laboratories account for the largest share of the market in 2026, with private reference laboratories representing a substantial portion of this segment given that clinical sequencing is funded predominantly through direct patient payments.
According to IARC GLOBOCAN 2022 estimates, Vietnam recorded 180,480 new cancer cases and 120,184 cancer deaths, with new cases nearly doubling within a decade and forecast to rise a further 45% by 2045. The VN1K project, conducted at the VinGroup Big Data Institute with approximately $4.5 million committed, analysed 1,011 individuals from 53 of Vietnam's 63 provinces and identified more than 42 million genetic variants, of which approximately 8.5 million had never been recorded in major international databases, producing the Vietnamese PanGenome Reference published in Nature Communications in July 2026. By October 2022, 66 gene sequencers had been installed across Vietnamese healthcare facilities, and the largest gene sequencing centre in Southeast Asia opened in Hanoi.
The key players operating in the Vietnam next generation sequencing market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), F. Hoffmann La Roche Ltd. (Switzerland), Revvity, Inc. (U.S.), Pacific Biosciences of California, Inc. (U.S.), Danaher Corporation (U.S.), Oxford Nanopore Technologies plc (U.K.), MGI Tech Co., Ltd. (China), BGI Genomics Co., Ltd. (China), Eurofins Scientific SE (Luxembourg), and Novogene Co., Ltd. (China). In 2025, Illumina held the leading position in this market at an estimated 20% to 24% share, followed by Thermo Fisher Scientific at 11% to 15%, MGI Tech at 8% to 11%, QIAGEN at 6% to 8%, and BGI Genomics at 5% to 7%.
The Vietnam next generation sequencing market study presents historical market data value (2024, 2025), estimated current data (2026), and forecasts for 2036. This market is segmented by offering, application, and end user.
Among all the offerings, Commercial Sequencing and Outsourced Services account for the largest share of the market in 2026, driven by the outsourcing of not only sequencing capabilities but also data interpretation, a capability that Vietnamese institutions often lack. Data Analysis and Bioinformatics is expected to register the highest CAGR, as software and outsourced analysis substitute for interpretive staff that institutions cannot readily recruit.
Among all the applications, Clinical Applications represent the largest share of the market in 2026. Within this segment, Non-Invasive Prenatal Testing (NIPT) accounts for the largest share, driven by direct out-of-pocket payment by parents and relatively limited interpretive requirements. Oncology, meanwhile, is expected to experience the highest growth rate as tumor mutation testing expands from a comparatively smaller existing base.
Among all the end users, Hospitals, Clinical and Reference Laboratories account for the largest share of the market in 2026, with private reference laboratories representing a substantial portion of this segment given that clinical sequencing is funded predominantly through direct patient payments.
Key Questions Answered in the Report:
- What is the current revenue generated by the Vietnam next generation sequencing market?
- At what rate is the Vietnam next generation sequencing market demand projected to grow through 2036?
- What are the historical market sizes and growth rates of the Vietnam next generation sequencing market?
- What are the major drivers of the Vietnam next generation sequencing market? What are the major restraints affecting the market?
- Which segments in terms of offering, application, and end user are expected to create major traction for the manufacturers in this market?
- Who are the major players in the Vietnam next generation sequencing market? What are their specific product offerings in this market?
- What are the recent strategic developments in the Vietnam next generation sequencing market? What are the impacts of these strategic developments on the market?
Table of Contents
1. Market Definition & Scope
2. Research Methodology
3. Executive Summary
4. Market Insights
5. Vietnam NGS Market Assessment, By Offering
6. Vietnam NGS Market Assessment, By Application
7. Vietnam NGS Market Assessment, By End User
8. Competitive Landscape
9. 9. Company Profiles
10. Appendix
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- Illumina, Inc.
- Thermo Fisher Scientific Inc.
- QIAGEN N.V.
- Agilent Technologies, Inc.
- F. Hoffmann La Roche Ltd.
- Revvity, Inc.
- Pacific Biosciences of California, Inc.
- Danaher Corporation
- Oxford Nanopore Technologies plc
- MGI Tech Co., Ltd.
- BGI Genomics Co., Ltd.
- Eurofins Scientific SE
- Novogene Co., Ltd. (China)
